02Aug
FDA Issues Cannabidiol Marketing Warning as Congressional Pressure for Action Continues
Following through with its promise to take enforcement actions against companies marketing cannabis-derived products that could put consumers at risk, the Food and Drug Administration (FDA) recently issued a warning letter to Curaleaf Inc., a...
By:
Wilson Sonsini Goodrich & Rosati
Related
PwC and CB Insights’ latest MoneyTree Report reports a 3% increase in U.S. venture capital deals th...
Read More >
Cannabidiol (CBD) – a non-psychoactive component of cannabis with numerous claimed health benefits ...
Read More >
Seyfarth Synopsis: On February 10, 2020, Judge Chutkan granted the Office of Management and Budget’...
Read More >
Many high-profile transactions impacted by the COVID-19 pandemic have fallen apart between signing a...
Read More >
The rising tide of state pay equity legislation shows no sign of abating, with several new laws set ...
Read More >
Japan's Ministry of Economy, Trade and Industry completely revised the 2007 MBO guidelines on June 2...
Read More >